Volume 31, Issue 2
February 2018
Cover image
Cover image
cover illustration Antibody Engineered Cysteine (EC) sites were selected to be proximal to the hinge and to coincide with the CD16 binding site (A). The solvent accessibility (B) and electrostatic potential (C) of these sites were examined for underlying trends that would explain differences in the maleimide stability of conjugated drug.
ISSN 1741-0126
EISSN 1741-0134
Issue navigation
Volume 31, Issue 2, February 2018
Original Articles
Improved cytotoxicity of novel TRAIL variants produced as recombinant fusion proteins
Protein Engineering, Design and Selection, Volume 31, Issue 2, February 2018, Pages 37–46, https://doi.org/10.1093/protein/gzx065
Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability
Protein Engineering, Design and Selection, Volume 31, Issue 2, February 2018, Pages 47–54, https://doi.org/10.1093/protein/gzx067
Development of novel metabolite-responsive transcription factors via transposon-mediated protein fusion
Protein Engineering, Design and Selection, Volume 31, Issue 2, February 2018, Pages 55–63, https://doi.org/10.1093/protein/gzy001
